• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Expansion

Advent, Sunstone et al. in $60m round for F2G

  • Alice Tchernookova
  • Alice Tchernookova
  • @alicetcherno
  • 20 June 2016
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

UK antifungal pharmaceutical company F2G has raised $60m funding in a round led by Sectoral Asset Management.

The round includes capital from new investors Novo, Aisling Capital and Brace Pharma Capital.

Previous investors also took part, including Advent Life Sciences, Novartis Venture Fund, Sunstone Capital and Merifin Capital.

F2G

  • DEAL:

    Expansion

  • VALUE:

    $60m

  • LOCATION:

    Manchester

  • SECTOR:

    Biotechnology

  • FOUNDED:

    1998

With the new financing, F2G plans to advance its lead compound, F901318 – a clinical-stage candidate for the treatment of invasive aspergillosis and other serious mould infections – and to further develop other earlier-stage assets in its pipeline.

Dr Maha Katabi, private equity partner at Sectoral Asset Management and Dr Martin Edwards, senior partner at Novo, will join the F2G board of directors.

Previous funding
In September 2002, BankInvest Biomedical Ventures led a £4.3m first round of funding for F2G. BankInvest provided £3m of the total from its Biomedical Venture Fund III, Merifin supplied £800,000 and the balance was provided by a small number of private investors.

In August 2003, a second funding round was provided by BankInvest and Merifin; the same investors injected an extra €4.52m in July 2004.

In March 2006, a €7.35m round involved BankInvest again, as well as Astellas Venture Management. In August 2008, BankInvest led an €8.01m round alongside minority investors Astellas and Merifin.

Then, in September 2012, Advent (via its Advent Life Sciences fund), Novartis, Sunstone, Merifin, K Nominees and Astellas invested a combined $30m (€23.91m) in an equity financing round.

Company
F2G is a Manchester-based biotech company focused on the discovery and development of therapies to treat life-threatening invasive fungal infections. It has mainly discovered and developed a new class of antifungal agents called the orotomides.

Established in 1998, F2G was formerly known as Functional Fungal Genomics.

People
Sectoral Asset Management – Dr Maha Katabi (private equity partner).
Novo – Dr Martin Edwards (senior partner).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Expansion
  • UK / Ireland
  • Healthcare
  • Venture
  • United Kingdom

More on Expansion

Wealth managers and financial advisers
Blackstone takes minority stake in Groupe Premium

Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn

  • Expansion
  • 31 July 2023
Risk and compliance management services
e-Attestations aims to triple size with new Keensight backing

Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019

  • Expansion
  • 25 July 2023
Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest - 3 July 2023

Unquote’s selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more

  • Expansion
  • 03 July 2023
Valentina Vitali of Limerston Capital
GP Profile: Limerston Capital anticipates higher volume but more complex M&A as market steadies

UK-based GP is seeing dealflow driven by carve-outs and buy-and-build in a market where organic multiple arbitrage is no longer a given

  • GPs
  • 07 June 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013